University of Rochester
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Rochester sits in the top decile of US sponsors by registered trial count (#53 of 15,742 sponsors by registered trial count).
University of Rochester: 636 sponsored US clinical trials, 94 recruiting.
University of Rochester sponsors 636 registered US clinical trials on ClinicalTrials.gov, 94 of them currently recruiting, and 448 completed. 54 of these trials are in Phase 3-4 (later-stage) and 147 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cancer, with 7 trials.
Top-decile sponsor footprint
University of Rochester ranks in the top decile of sponsors by registered trial count (#53 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
448 of 506 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
636 total, page 9 of 13
Functional and Lymphocytic Markers of Respiratory Morbidity in Hyperoxic Preemies
NCT01607216
Cellcept for Treatment of Juvenile Neuronal Ceroid Lipofuscinosis
NCT01399047
Interpersonal Psychotherapy for Adolescent Girls
NCT01534377
Clinical Efficacy Trial of Mexiletine for Myotonic Dystrophy Type 1
NCT01406873
Objective Evaluation of Ocular Surface Lubricants in Two Environments
NCT01375582
eMOMS of Rochester
NCT01331564
Imexon for Relapsed Follicular and Aggressive Lymphomas
NCT01314014
Hormones and Cognition in the Menopausal Transition
NCT01429103
Oral Ketamine for Control of Chronic Pain in Children
NCT01369680
Comparing Diabetes Prevention Programs
NCT01409889
Ozone Cardiovascular Effects in Genetically Susceptible People
NCT01192477
Pilot Study of Feasibility of Outpatient Daily High Dose Cytarabine as Consolidation Therapy for Older Patients With Acute Myeloid Leukemia (AML)
NCT02101983
VOICE: Values and Options in Cancer Care
NCT01485627
Daptomycin Versus Placebo in Patients With Neutropenia and Fever
NCT01216241
Pioglitazone in Early Parkinson's Disease
NCT01280123
Conditioned Pharmacotherapeutic Effects in Hypertension
NCT02056626
Use of Saline-Washed Platelet and Red Cell Transfusions in Adult Acute Leukemia
NCT01976442
Virtual Clinician Research Tool
NCT01408758
Study of Carfilzomib and Vorinostat for Relapsed or Refractory Lymphoma
NCT01276717
Gemcitabine, Oxaliplatin and Panitumumab in Kras/B-raf Wild-Type Biliary Track and Gallbladder Cancer
NCT01308840
Assessment of Prototype Hand-held Fundus Camera
NCT01244412
Lubiprostone in Patients With Multiple Sclerosis Associated Constipation
NCT01236534
Effect of a Commonly Used Antibiotic, Doxycycline, in Women With Polycystic Ovarian Syndrome
NCT01788215
The Effects of Physical Activity and Low-Dose Ibuprofen on Cognitive Function in Cancer Patients
NCT01238120
The Qutenza Patch as Treatment for Disabling Treprostinil (Remodulin) Infusion Site Pain
NCT01260454
Effects of High Dose Calcitriol in Breast Cancer Patients
NCT01293682
Memantine for Recurrent Glioblastoma
NCT01260467
Positron Emission Tomography - Computed Tomography (PET-CT) Scanning in Chronic Graft Versus Host Disease (cGvHD)
NCT01964625
Study Of Telemedicine Consultation at Home For Older Adults
NCT01324687
Effect of Age and Prior Immunity to Response to Seasonal Influenza Vaccines in Children
NCT01246999
Certolizumab and Lower Extremity Lymph Flow in Rheumatoid Arthritis (RA)
NCT01098201
Social and Behavioral Influence (SBI)
NCT01501006
Use of Cell Salvage Post-operatively in Infants to Decrease Use of Allogeneic Blood Product Transfusions
NCT01211366
Prophylactic Phenobarbital After Neonatal Seizures
NCT01089504
School-Based Preventive Asthma Care Technology: A Trial Using a Novel Technology to Improve Adherence
NCT01175434
Fish Oil and Aspirin With Type 2 Diabetes
NCT01181882
Effectiveness Trial of Youth Suicide Prevention Delivered by Teen Peer Leaders
NCT02043093
Non-invasive Ocular Surface Measurements Before and After Interventions
NCT01228929
Three-dimensional Craniofacial Phenotyping of Patients With Difficult Airway
NCT01630694
National Psoriasis Foundation - Dendritic Cell-Specific Transmembrane Protein (DC-Stamp) Biomarker Study
NCT01123265
Non-invasive Tear Film Dynamic Measurements in Normal, MGD and ADDE Subjects After Saline Instillation
NCT01128049
The Effects of Lovaza® in Acute Myocardial Infarction
NCT01155336
Pilot Study of Fosamax in Spinal Cord Injury
NCT01131884
Total Skeletal Irradiation in Multiple Myeloma Before Second Autologous Hematopoietic Stem Cell Transplantation
NCT01182233
Usefulness of Dexmedetomidine on Post-operative Pain Management in Patients With Interstitial Cystitis
NCT01195116
Impact of Pelvic Floor Musculature on Peripartum Outcomes
NCT01208246
Temporal Pattern of Circulating DNA for Patients Receiving Irradiation
NCT01099020
Role of 3D Tomography in Breast Cancer
NCT01090687
Effects of Age on Response to the 2009 H1N1 Virus Vaccine
NCT01055184
Improving Psoriasis Through Health and Well-Being
NCT01162252
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 66 |
| Phase 2 | 81 |
| Phase 3 | 20 |
| Phase 4 | 34 |
Therapeutic Areas
What is open in the University of Rochester pipeline
94 recruiting of 636 indexed (15% open); 448 completed (70%).
Phase mix: 54 late (III/IV) vs 147 early (I/II) (early-phase heavy).
Top condition: Cancer (7 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Rochester: open-pipeline peers nationwide
Peers matched on 636 registered trials and 15% open enrollment, not the therapeutic-area sidebar.
University of Rochester sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 636 trials (± recruiting share)
- US Department of Veterans Affairs · 632 trials · 0% recruiting
- University of Southern California · 617 trials · 16% recruiting
- Baylor College of Medicine · 616 trials · 15% recruiting
- University of California, Davis · 657 trials · 19% recruiting
Sponsors near 15% open enrollment (± trial volume)
- Loma Linda University · 15% recruiting · 237 trials
- Dompé Farmaceutici S.p.A · 15% recruiting · 27 trials
- Vanderbilt-Ingram Cancer Center · 15% recruiting · 189 trials
- Brown University · 15% recruiting · 231 trials
Related
What to do with this University of Rochester page
636 registered trials is a research-attention snapshot, not an endorsement of University of Rochester or any single study.
- 94 of University of Rochester's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Cancer is the condition University of Rochester studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. University of Rochester pipeline card: 636 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.